BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Circulating tumour DNA as a biomarker of genetics alterations in c
 ancer  - Florent Mouliere (IRCM U896 Inserm\, Montpellier\, France)
DTSTART:20130128T160000Z
DTEND:20130128T170000Z
UID:TALK42824@talks.cam.ac.uk
CONTACT:Florian Markowetz
DESCRIPTION:Circulating tumour DNA as a biomarker of genetics alterations 
 in cancer. Application to the quantitative determination of KRAS and BRAF 
 mutations in plasma of colorectal cancer patients.\n\nThe pressing need to
  determine the KRAS mutational status for selecting patients with colorect
 al cancer for anti-EGFR therapy provides a great opportunity to use circul
 ating tumor DNA (ctDNA) as a theranostic tool. However the determination o
 f genetic alteration in ctDNA could benefit of a better knowledge of ctDNA
 \, especially at the structural level. \n\nWe accumulated data on ctDNA st
 ructural characteristics enabling us to develop a specific ctDNA methodolo
 gy. Intplex is based on Allele Specific Blocker Q-PCR\, and consequently i
 s simple\, fast\, and cost effective\, and can discriminate targeted point
  mutation from even single copies of ctDNA. KRAS and BRAF mutations are dr
 iven mutations in CRC (colorectal cancer) and affect treatment outcome. In
 tplex was adapted to detect seven KRAS (G12V\, G12D\, G13D\, G12S\, G12A\,
  G12C\, G12R) and one BRAF V600E point mutations. KRAS and BRAF mutational
  status was determined with high concordance when comparing ctDNA analysis
  and conventional methods from tumor tissue section\, and greater sensitiv
 ity (0.01% mutant/WT ratio). \n\nWe showed that CRC plasma analysis could 
 replace advantageously tumour-section analysis of targeted point mutation 
 and expand the scope of personalized medicine for cancer patients.\n\nHost
 ed by Nitzan Rosenfeld\n
LOCATION:Cancer Research UK Cambridge Institute\, Lecture Theatre
END:VEVENT
END:VCALENDAR